{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:39:38Z","timestamp":1762987178877,"version":"3.45.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jtocrr.2021.100147","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:54:19Z","timestamp":1611057259000},"page":"100147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC"],"prefix":"10.1016","volume":"2","author":[{"given":"Ferr\u00e9ol","family":"Roborel de Climens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Poulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Stoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis Benjamin","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Dhalluin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Gauvain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2021.100147_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtocrr.2021.100147_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020;70:313]","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2021.100147_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.rmed.2017.01.002","article-title":"Obtaining tissue diagnosis in lung cancer patients with poor performance status and its influence on treatment and survival","volume":"124","author":"Maclay","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jtocrr.2021.100147_bib4","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1002\/cncr.27658","article-title":"Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy","volume":"118","author":"Small","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2021.100147_bib5","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2019;30:863\u2013870]","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib6","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for Stage IV non\u2013small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update [published correction appears in J Clin Oncol. 2018;36:304","volume":"35","author":"Hanna","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/cancers10070236","article-title":"A\u00a0review of recent advances in the treatment of elderly and poor performance NSCLC","volume":"10","author":"Carmichael","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2021.100147_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.1986.4.1.14","article-title":"A\u00a0randomized trial of the four most active regimens for metastatic non-small-cell lung cancer","volume":"4","author":"Ruckdeschel","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib9","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8","article-title":"Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma","volume":"92","author":"Sweeney","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2021.100147_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12904-019-0427-4","article-title":"Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status","volume":"18","author":"Fiorin de Vasconcellos","year":"2019","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.jtocrr.2021.100147_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1200\/JCO.2004.08.136","article-title":"Trends in the aggressiveness of cancer care near the end of life","volume":"22","author":"Earle","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100147_bib13","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100147_bib14","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100147_bib15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100147_bib16","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100147_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2021.100147_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations","volume":"127","author":"Felip","year":"2020","journal-title":"Eur J Cancer"},{"issue":"suppl 5","key":"10.1016\/j.jtocrr.2021.100147_bib19","first-page":"v460","article-title":"IFCT-1502 CLINIVO: real life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)","volume":"28","author":"Girard","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtocrr.2021.100147_bib21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib22","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1477-7525-8-104","article-title":"Health care providers underestimate symptom intensities of cancer patients: a multicenter European study","volume":"8","author":"Laugsand","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jtocrr.2021.100147_bib24","series-title":"Annual Update in Intensive Care and Emergency Medicine","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-030-06067-1_3","article-title":"Acute respiratory failure in the\u00a0oncologic patient: New Era, new issues","author":"Ferreyro","year":"2019"},{"key":"10.1016\/j.jtocrr.2021.100147_bib25","series-title":"Mechanical Ventilation in Critically Ill Cancer Patients","first-page":"21","article-title":"Acute respiratory failure in patients with hematologic and solid malignancies: global approach","author":"Sethi","year":"2018"},{"key":"10.1016\/j.jtocrr.2021.100147_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21037\/jtd.2018.12.47","article-title":"Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients\u2019 treatment","volume":"11","author":"Onesti","year":"2019","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtocrr.2021.100147_bib27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1470-2045(12)70412-6","article-title":"First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib28","unstructured":"Inivata. TIMELY: multicentre phase II trial of first-line afatinib in patients with suspected\/confirmed EGFR mutant NSCLC - ctDNA & long-term efficacy. https:\/\/www.inivata.com\/wp-content\/uploads\/2018\/11\/TIMELY-poster-ref-11908-IASLC-2018-online-version.pdf. Accessed April 4, 2020."},{"key":"10.1016\/j.jtocrr.2021.100147_bib29","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2007.15.2280","article-title":"Erlotinib for advanced non\u2013small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21","volume":"26","author":"Wheatley-Price","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lungcan.2014.09.015","article-title":"Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer","volume":"86","author":"Yoshioka","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100147_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/onco.13561","article-title":"Clinical outcomes of patients with metastatic cancer receiving immune checkpoint inhibitors in the inpatient setting","volume":"26","author":"Durbin","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jtocrr.2021.100147_bib32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100147_bib33","unstructured":"A phase II single-arm trial evaluating safety and efficacy of durvalumab in ECOG performance status;2\u20133, treatment-naive, patients with stage IV non-small cell lung cancer (NSCLC) and high PD-L1 tumor expression (NCT04108026). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04108026. Accessed May 12,\u00a02020."}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:36:03Z","timestamp":1762986963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364321000060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2666364321000060"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100147","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100147"}}